Swai, Johnson Kyeba
Kibondo, Ummi Abdul
Ntabaliba, Watson Samuel
Ngoyani, Hassan Ahamad
Makungwa, Noely Otto
Mseka, Antony Pius
Chura, Madeleine Rose
Mascari, Thomas Michael
Moore, Sarah Jane
Article History
Received: 13 October 2022
Accepted: 20 April 2023
First Online: 29 April 2023
Declarations
:
: Written informed consent was obtained from all study participants prior to commencement of the study. All study volunteers were provided with Doxycycline<sup>®</sup> malaria prophylaxis as per Tanzania Guidelines for Diagnosis and Treatment of Malaria [CitationRef removed] and tested weekly for malaria infection using malaria rapid diagnostic tests (SD Bioline) administered by a medical officer. No volunteers tested positive for malaria throughout the duration of this study. No adverse effects were reported among the volunteers throughout the duration of the study. Study activities were approved by the Institutional Review Board of IHI IHI/IRB/EXT/No: 14-2022 and National Institute for Medical Research Tanzania (NIMR/HQ/R.8a/Vol. IX/3744).
: Permission to publish this study was obtained from National Institute for Medical Research NIMR/HQ/P.12 VOL XXXV/57.
: The authors JKS, UAK, WSN, HAN, NOM, APM and SJM conduct product evaluations for companies that produce vector control products including S.C. Johnson. MRC and TMM are employed by S.C. Johnson, Inc, Racine, Wisconsin.